Report source: nicole carnt, jeremy hoffman, seema verma, cherry radford, darwin c.Minassian and john k.G.Dart: acanthamoeba keratitis: confirmation of a current uk outbreak and a prospective case control study identifying contributing risk factors.(b)(4).
|
On 23 march 2018, an email was received from an eye care professional (ecp).The ecp is the author of a prospective study, conducted in the uk, that has been submitted for publication in 2018.The email contained an attached summary data spreadsheet containing the medical information for subjects involved in the prospective acanthamoeba keratitis study.The information received from the ecp included only those study subjects who reported wearing acuvue brand products at the time of the adverse event.All the study subjects were initially examined and diagnosed with acanthamoeba keratitis during 2011-2014.The patient (pt), study id 47, was initially diagnosed with hsv keratitis after experiencing severe pain, photophobia, redness, watery eye with poor vision od.The pt was treated with topical steroids for six months prior to being referred to the hospital on (b)(6) 2011 where the pt was diagnosed with acanthamoeba keratitis od.The pt reported wearing 1 day acuvue brand contact lenses.The reporting eye care professional indicated there were ¿no extenuating circumstances¿ prior to the pt developing symptoms.The pt was treated with antiamoebics for 2 years, 3 months and topical steroids od after being diagnosed.The pt subsequently developed glaucoma.Additional treatment included: superficial keratectomy, penetrating keratoplasty x2, cryotherapy, botox, gluing and enucleation of the od.No additional information is expected to be received.The lot number of the suspect product is unknown.Suspect product is not available for return for evaluation.If additional information is received it will be reported within 30 days of receipt.Serious reportable event trends are reviewed quarterly in franchise management review meetings.
|